

Ensemble Discovery Appoints David J. Livingston, PhD as Sr. Vice President, Biology

Cambridge, MA (July 23, 2007)—Ensemble Discovery Corporation today announced the appointment of David J. Livingston, PhD to the role of Sr. Vice President, Biology. In this capacity, Dr. Livingston will lead Ensemble Discovery's biodetection program.

Dr. Livingston joins Ensemble at a time when the Company's biodetection program is making rapid progress using its DNA Programmed Chemistry™ to develop unique tissue-based diagnostics for the detection and characterization of protein function, including protein homo- and heterodimers, to better target treatments for cancer and other diseases.

Dr. Livingston has more than 20 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Ensemble, Dr. Livingston was President of Biomedical Strategies Consulting, where he advised biotechnology clients on new therapeutic targets and technologies for drug development. Prior to consulting, Dr. Livingston was President and CEO of Spherics, Inc., a drug delivery company, and Praelux Inc. (now part of GE Healthcare), which invented a rapid confocal imaging platform for high-content cell assay--based drug discovery. Dr. Livingston also led biology efforts at Integrated Genetics and Vertex Pharmaceuticals in therapeutic areas such as thrombolysis, inflammation, immunology, and virology. He is an inventor on 23 US patents and is a co-author on more than 60 peer reviewed publications.

Dr. Livingston holds a PhD from the University of California at Davis, an MBA from Northeastern University in Boston, and a BS from the University of Massachusetts at Amherst.

About Ensemble Discovery

Based in Cambridge, MA, Ensemble Discovery Corporation is harnessing a fundamentally new approach to controlling chemical reactivity to develop novel classes of therapeutics and bioassays. Ensemble Discovery is deploying DNA-Programmed Chemistry (DPC™), a proprietary platform, based on the groundbreaking work of Professor David Liu of Harvard University. In its drug discovery programs, Ensemble uses DPC to generate Programmed Macrocycles™ as drug candidates for pharmaceutically challenging targets. In its diagnostic programs, Ensemble uses DPC to control the generation of detection signals in response to the presence of specific molecular events underlying human diseases. DPC-based assays are particularly adept at the detection of dimeric molecules such as growth factor receptors on cell surfaces. Ensemble's BCR-ABL detection program is funded in part by The Leukemia & Lymphoma Society. Ensemble is the first company to receive funding by The LLS under a new initiative to accelerate the development of blood cancer therapies.

For More Information, Contact:

Edward Freedman
Ensemble Discovery Corporation
(617) 492-6977
efreedman@enssemblediscovery.com